Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)

Lipids in Health and Disease

Volumn 16, Issue 1, 2017, Pages 1-13

  Brinton, Eliot A ^a   Mason, R Preston ^b  

^a Utah Foundation for Biomedical Research   (United States)

^b ELUCIDA RESEARCH LLC   (United States)

Author keywords

Cardiovascular disease; Cholesterol; Drug therapy; Eicosapentaenoic acid; Ethyl icosapentate; Hypertriglyceridemia; Icosapent ethyl; Inflammation; Omega 3 fatty acids; Triglycerides

Indexed keywords

ATORVASTATIN; DOCOSAHEXAENOIC ACID; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; OMEPRAZOLE; PITAVASTATIN; PLACEBO; PRAVASTATIN; PRESCRIPTION DRUG; ROSIGLITAZONE; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN; ETHYL EICOSAPENTAENOIC ACID;

ATHEROGENESIS; BRAIN HEMORRHAGE; CARDIOVASCULAR EFFECT; CORONARY ARTERY DISEASE; DIARRHEA; DIETARY SUPPLEMENT; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECZEMA; EPIGASTRIC DISCOMFORT; EPISTAXIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; NAUSEA; PRESCRIPTION; PRURITUS; RASH; REVIEW; SUBCUTANEOUS HEMORRHAGE; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; UTILIZATION;

DIETARY SUPPLEMENTS; DRUG PRESCRIPTIONS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS;

EID: 85010858391     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-017-0415-8     Document Type: Review

References (101)

1. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem. 2010;21:781-92.
2. Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med. 2014;126:7-18.
3. Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res. 2012;53:2525-45.
4. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr. 2004;79:935-45.
5. Mason RP, Jacob RF. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim Biophys Acta. 2015;1848:502-9.
6. Breivik H, Haraldsson GG, Kristinsson B. Preparation of highly purified concentrates of eicosapentaenoic acid and docosahexaenoic acid. J Am Oil Chem Soc. 1997;74:1425-9.
7. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, plAcebo-controlled, randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial). Am J Cardiol. 2011;108:682-90.
8. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984-92.
9. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6:5-18.
10. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242:357-66.
11. Mason RP, Jacob R, Beauregard G, Rowe J. Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors [abstract]. J Clin Lipidol. 2011;5:201.
12. Mason RP, Jacob RF, Corbalan JJ, Malinski T. Combination eicosapentaenoic acid and statin treatment reversed endothelial dysfunction in HUVECs exposed to oxidized LDL [abstract 160]. J Clin Lipidol. 2014;8:342-3.
13. Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. J Cardiovasc Pharmacol. 2016;68:33-40.
14. Toyama K, Nishioka T, Isshiki A, Ando T, Inoue Y, Kirimura M, Kamiyama T, Sasaki O, Ito H, Maruyama Y, Yoshimoto N. Eicosapentaenoic acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther. 2014;28:53-9.
15. Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J. 2012;59:297-304.
16. Takaki A, Umemoto S, Ono K, Seki K, Ryoke T, Fujii A, Itagaki T, Harada M, Tanaka M, Yonezawa T, et al. Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study. J Atheroscler Thromb. 2011;18:857-66.
17. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003;361:477-85.
18. Nishio R, Shinke T, Otake H, Nakagawa M, Nagoshi R, Inoue T, Kozuki A, Hariki H, Osue T, Taniguchi Y, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234:114-9.
19. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:252-9.
20. Dangardt F, Osika W, Chen Y, Nilsson U, Gan LM, Gronowitz E, Strandvik B, Friberg P. Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents. Atherosclerosis. 2010;212:580-5.
21. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13:37-46.
22. Tanaka N, Ishida T, Nagao M, Mori T, Monguchi T, Sadaki M, Mori K, Kondo K, Nakajima H, Honjo T, et al. Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis. 2014;237:577-83.
23. Yamano T, Kubo T, Shiono Y, Shimamura K, Orii M, Tanimoto T, Matsuo Y, Ino Y, Kitabata H, Yamaguchi T, et al. Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study. J Atheroscler Thromb. 2015;22:52-61.
24. Uehara H, Miyagi N, Shimajiri M, Nago C. The additional effect of eicosapentanoic acid on coronary plaque stability in stable angina patients with statin use by optical coherence tomography analysis [abstract P5495]. Eur Heart J. 2013;34 suppl 1:1011.
25. Niki T, Wakatsuki T, Yamaguchi K, Taketani Y, Oeduka H, Kusunose K, Ise T, Iwase T, Yamada H, Soeki T, Sata M. Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound. Circ J. 2016;80:450-60.
26. Domei T, Amemiya K, Enomoto S, Ichihashi K, Yokoi H, Iwabuchi M, Nobuyoshi M. Eicosapentaenoic acid reduced the progression of the coronary atherosclerosis in the patients with optimal LDL cholesterol lowering therapy [abstract P689]. Eur Heart J. 2013;34 suppl 1:137.
27. Nagahara Y, Motoyama S, Sarai M, Ito H, Kawai H, Miyajima K, Naruse H, Ishii J, Ozaki Y. The impact of eicosapentaenoic acid on prevention of plaque progression detected by coronary computed tomography angiography [abstract P5235]. Eur Heart J. 2016;37 suppl 1:1052.
28. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after PCI to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol. 2010;55:1671-8.
29. Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y. Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes. J Atheroscler Thromb. 2009;16:83-90.
30. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047-67.
31. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8:473-88.
32. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889-934.
33. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, et al. Executive summary of the Japan atherosclerosis society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version. J Atheroscler Thromb. 2013;20:517-23.
34. Epadel [package insert, 2015 and pharmaceutical interview form, 2013]. Tokyo, Japan: Mochida Pharmaceutical Co., Ltd; 2015.
35. Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2016.
36. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-8.
37. Braeckman RA, Stirtan WG, Soni PN. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. Clin Drug Investig. 2015;35:45-51.
38. Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters. Clin Drug Investig. 2014;34:449-56.
39. Braeckman RA, Stirtan WG, Soni PN. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects. Clin Pharmacol Drug Dev. 2015;4:143-8.
40. Braeckman RA, Stirtan WG, Soni PN. Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults. Drugs R D. 2014;14:159-64.
41. Wachira JK, Larson MK, Harris WS. n-3 fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr. 2014;111:1652-62.
42. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99:35C-43C.
43. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 2007;99:44C-6C.
44. Yokoyama M, Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA lipid intervention study (JELIS). Am Heart J. 2003;146:613-20.
45. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS). Atherosclerosis. 2008;200:135-40.
46. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA lipid intervention study (JELIS). Atherosclerosis. 2009;206:535-9.
47. Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J. 2010;74:1451-7.
48. Sasaki J, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Itakura H, Hishida H, Kita T, et al. Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA lipid intervention study (JELIS). J Atheroscler Thromb. 2012;19:194-204.
49. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009;73:1283-90.
50. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008;39:2052-8.
51. Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circ J. 2010;74:510-7.
52. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Kita T, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18:99-107.
53. Randomized trial for evaluation in secondary prevention efficacy of combination therapy - statin and eicosapentaenoic acid UMIN000012069 [https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000014051&type=summary&language=E].
54. Watanabe T, Miyamoto T, Miyasita T, Shishido T, Arimoto T, Takahashi H, Nishiyama S, Hirono O, Matsui M, Sugawara S, et al. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-rationale and design. J Cardiol. 2014;64:236-9.
55. Ando K, Watanabe T, Daidoji H, Otaki Y, Hashimoto N, Kumagai Y, Hashimoto N, Narumi T, Kadowaki S, Yamaura G, et al. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography: a randomized controlled trial [abstract 12007]. Circulation. 2015;132:A12007.
56. Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12:100.
57. Braeckman R, Manku MS, Ballantyne CM, Stirtan WG, Soni PN. Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Circulation. 2012;126:A18549.
58. Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukot Essent Fatty Acids. 2013;89:195-201.
59. Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012;6:565-72.
60. Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle Jr RT, Soni PN, Juliano RA. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol. 2015;9:377-83.
61. Ballantyne CM, Bays HE, Philip S, Doyle RTJ, Braeckman RA, Stirtan WG, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016;253:81-7.
62. Toth PP, Bays HE, Brown WV, Tomassini JE, Wang C, Polis AB, Tershakovec AM. Cholesterol in remnant-lipoproteins as measured by different methods [poster]. In: March 14-16, 2015; San Diego, CA. Annual scientific sessions of the American college of cardiology. 2015.
63. Toth PP, Bays H, Brown W, Tomassini J, Wang C, Polis A, Tershakovec A. Cholesterol in remnant-lipoproteins as measured by different methods [abstract]. J Am Coll Cardiol. 2015;65:A1569.
64. Jones SR, Martin SS, Brinton EA. Letter by Jones et al. Regarding article, “elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation”. Circulation. 2014;129:e655.
65. Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141:358-67.
66. Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle Jr RT, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016;10:635-45.
67. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008;114:611-24.
68. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). [http://clinicaltrials.gov/show/NCT01492361].
69. Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.
70. Epanova [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2016.
71. Omtryg [package insert]. Arlington, VA: Trygg Pharma, Inc.; 2014.
72. Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis. 2013;230:381-9.
73. Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the national library of medicine herbal supplement database. Metab Syndr Relat Disord. 2011;9:255-71.
74. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006;83:1467S-76S.
75. Kastelein JJP, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr lowering very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8:94-106.
76. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474-83.
77. Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D, Davidson M. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag. 2013;9:563-73.
78. Dawson K, Zhao L, Adkins Y, Vemuri M, Rodriguez RL, Gregg JP, Kelley DS, Hwang DH. Modulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men. J Nutr Biochem. 2012;23:616-21.
79. Ishida T, Ohta M, Nakakuki M, Kami H, Uchiyama R, Kawano H, Notsu T, Imada K, Shimano H. Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: participation of cholesterol ester transfer protein and LDL receptor. Prostaglandins Leukot Essent Fatty Acids. 2013;88:281-8.
80. Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care. 2016;25:46-52B.
81. Regulatory information: Dietary supplement health and education act of 1994 [http://health.gov/dietsupp/ch1.htm].
82. Lopez JAG, Ito MK. PLA chapter update: prescription fish oil and blue cross of Idaho. LipidSpin. 2010;8:32-4.
83. Cohen PA. Hazards of hindsight-monitoring the safety of nutritional supplements. N Engl J Med. 2014;370:1277-80.
84. Dietary supplements: what is safe? [http://www.cancer.org/acs/groups/cid/documents/webcontent/002385-pdf.pdf].
85. Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the united states. J Sci Food Agric. 2015;95:1260-7.
86. Albert BB, Derraik JG, Cameron-Smith D, Hofman PL, Tumanov S, Villas-Boas SG, Garg ML, Cutfield WS. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928.
87. Ritter JC, Budge SM, Jovica F. Quality analysis of commercial fish oil preparations. J Sci Food Agric. 2013;93:1935-9.
88. Shim SM, Santerre CR, Burgess JR, Deardorff DC. Omega-3 fatty acids and total polychlorinated biphenyls in 26 dietary supplements. J Food Sci. 2003;68:2436-40.
89. Mason RP, Hilleman DE. Omega-3 fatty acid fish oil dietary supplements for disease management: are they appropriate for patients? LipidSpin. 2016;14. https://www.lipid.org/node/1903.
90. Mason P, Sherratt S. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. 2016. Epub ahead of print.
91. Bradberry JC, Hilleman DE. Overview of omega-3 fatty acid therapies. P T. 2013;38:681-91.
92. Halvorsen BL, Blomhoff R. Determination of lipid oxidation products in vegetable oils and marine omega-3 supplements. Food Nutr Res. 2011;55. DOI: 10.3402/fnr.v3455i3400.5792.
93. Rupp H, Rupp KG. Adverse effects of ethyl esters or oxidation products in omega-3 preparations? Cardiovasc J Afr. 2014;25:86-7.
94. Mason R, Sherratt S. Analysis of omega-3 fatty acid dietary supplements with respect to content: are they appropriate for patients? [abstract E21]. J Manag Care Spec Pharm. 2015;21:S34.
95. Albert BB, Cameron-Smith D, Hofman PL, Cutfield WS. Oxidation of marine omega-3 supplements and human health. Biomed Res Int. 2013;2013:464921.
96. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, Mason RP. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol. 2004;44:1996-2002.
97. Mason RP, Jacob RF, Shrivastava S, Sherratt SC, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858:3131-40.
98. Bays HE, Ballantyne CM, Doyle Jr RT, Juliano RA, Philip S. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016;125:57-64.
99. Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Tsukuda S, Yokohama F, Sogo M, Nishibe T, Matsuo N, et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. Int J Cardiol. 2016;228:173-9.
100. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155-63.
101. Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin Pharmacol Drug Dev. 2014;3:101-8.